Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2007

View Archived Issues

Recent Incyte patent reports novel agents for HIV infection

Novel agents for cardiovascular disorders disclosed in recent patents

RANKL: Target To Watch for development of therapeutics for treatment of osteolytic bone disorders

Biota and MedImmune begin RSV drug phase Ia clinical trials in adults

Patient enrollment on target for Avicena's phase III Parkinson's disease trial

Neuroprotective activity of olomoucine seen in status epilepticus model

Urigen completes reverse merger with Valentis

Aquinox describes development of SHIP inhibitor MN-100

Positive initial phase I findings for FLAP inhibitor AM-103

Dual CB1/CB2 agonist from Novartis has antihyperalgesic activity

Organon and Dyax partner in autoimmune diseases and cancer

Manufacturing agreement signed for GMP production of hGH-CTP

Centrix signs manufacturing and supply agreement with Cedar for Northyx

Recent patents disclose new therapeutic agents for anxiety, depression, etc.

NicOx/Merck & Co. drug candidate enters phase I trial triggering milestone payment

Series A financing at GlycoVaxyn

ImmuPharma's files IND for pivotal phase II/III trial for lupus

BioCryst and Roche to begin phase II study of BCX-4208 for psoriasis

Millennium begins phase III trial of Velcade for newly diagnosed MM

ProMetic BioSciences and Darier to codevelop PBI-1308

Amgen acquires Alantos Pharmaceuticals

Positive results for BioLineRx's study of first-in-class GABA-enhanced antipsychotic

Update on Hollis-Eden's phase I trial of HE-3286 for type 2 diabetes

Second approvable letter for eprodisate

Newest addition to Integrity's Disease Briefings collection sheds light on malaria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...